Highlights Fusen Pharmaceutical Company Limited

Equities

1652

KYG370981030

Market Closed - Hong Kong S.E. Other stock markets 01:38:32 29/05/2024 pm IST			5-day change	1st Jan Change
1.2 ^HKD	0.00%		+4.35%	-12.41%

04/04	Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	MT
03/04	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	04/04	MT
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	03/04	CI
Fusen Pharmaceutical Posts Higher Loss in 2023	01/04	MT
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	15/03	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Fusen Pharmaceutical Forecasts Return to Profitability in H1	11/23/11	MT
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	10/23/10	CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.	31/23/31	CI
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.	30/23/30	CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	28/23/28	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022	28/23/28	CI
Fusen Pharmaceutical to Swing to Loss in 2022	14/23/14	MT
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022	13/23/13	CI
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches	04/23/04	MT
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	29/22/29	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022	29/22/29	CI
Fusen Pharmaceutical Forecasts Swing to Loss in January-June Results	22/22/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fusen Pharmaceutical Company Limited

Equities

1652

KYG370981030

Highlights

Filters